KALA BIO, Inc. (KALA) stock
KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.43−0.40 (-10.44%)
Close on Nov 17, 2026Market cap $66.34MP/E –Yield –
Kala Bio cash
Cash and short-term investments held at the end of each period.
Kala Bio's cash was $7.23M at Jun 30, 2026. For fiscal 2025 it was $7.56M, down 85.2% from the year before. Over ten years it grew 2.8% a year on average. The highest annual figure on record is $170.90M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.56M | -85.2% |
| FY2024 | Dec 31, 2024 | $51.18M | +0.6% |
| FY2023 | Dec 31, 2023 | $50.90M | -27.8% |
| FY2022 | Dec 31, 2022 | $70.50M | -23.5% |
| FY2021 | Dec 31, 2021 | $92.14M | -40.0% |
| FY2020 | Dec 31, 2020 | $153.54M | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2018 | Dec 31, 2018 | $170.90M | +49.0% |
| FY2017 | Dec 31, 2017 | $114.70M | +151.6% |
| FY2016 | Dec 31, 2016 | $45.58M | +691.5% |
| FY2015 | Dec 31, 2015 | $5.76M | -46.3% |
| FY2014 | Dec 31, 2014 | $10.73M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.23M | -77.4% |
| Q1 FY2026 | Mar 31, 2026 | $8.76M | -79.2% |
| Q4 FY2025 | Dec 31, 2025 | $7.56M | -85.2% |
| Q3 FY2025 | Sep 30, 2025 | $21.10M | -57.1% |
| Q2 FY2025 | Jun 30, 2025 | $31.94M | -41.1% |
| Q1 FY2025 | Mar 31, 2025 | $42.22M | -12.9% |
| Q4 FY2024 | Dec 31, 2024 | $51.18M | +0.6% |
| Q3 FY2024 | Sep 30, 2024 | $49.20M | -12.2% |
| Q2 FY2024 | Jun 30, 2024 | $54.20M | -8.4% |
| Q1 FY2024 | Mar 31, 2024 | $48.48M | -23.8% |
| Q4 FY2023 | Dec 31, 2023 | $50.90M | -27.8% |
| Q3 FY2023 | Sep 30, 2023 | $56.06M | +7.0% |
| Q2 FY2023 | Jun 30, 2023 | $59.18M | +32.8% |
| Q1 FY2023 | Mar 31, 2023 | $63.64M | -9.3% |
| Q4 FY2022 | Dec 31, 2022 | $70.50M | -23.5% |
| Q3 FY2022 | Sep 30, 2022 | $52.39M | -57.9% |
| Q2 FY2022 | Jun 30, 2022 | $44.57M | -70.2% |
| Q1 FY2022 | Mar 31, 2022 | $70.16M | -55.0% |
| Q4 FY2021 | Dec 31, 2021 | $92.14M | -40.0% |
| Q3 FY2021 | Sep 30, 2021 | $124.50M | -21.8% |
| Q2 FY2021 | Jun 30, 2021 | $149.64M | -18.9% |
| Q1 FY2021 | Mar 31, 2021 | $155.99M | -20.6% |
| Q4 FY2020 | Dec 31, 2020 | $153.54M | – |
| Q3 FY2020 | Sep 30, 2020 | $159.12M | +63.1% |
| Q2 FY2020 | Jun 30, 2020 | $184.56M | +56.4% |
| Q1 FY2020 | Mar 31, 2020 | $196.46M | +41.4% |
| Q4 FY2019 | Dec 31, 2019 | $0 | -100.0% |
| Q3 FY2019 | Sep 30, 2019 | $97.56M | +30.2% |
| Q2 FY2019 | Jun 30, 2019 | $118.01M | +29.4% |
| Q1 FY2019 | Mar 31, 2019 | $138.94M | +38.2% |
| Q4 FY2018 | Dec 31, 2018 | $170.90M | +49.0% |
| Q3 FY2018 | Sep 30, 2018 | $74.91M | -38.6% |
| Q2 FY2018 | Jun 30, 2018 | $91.21M | +246.1% |
| Q1 FY2018 | Mar 31, 2018 | $100.53M | +179.1% |
| Q4 FY2017 | Dec 31, 2017 | $114.70M | +151.6% |
| Q3 FY2017 | Sep 30, 2017 | $122.05M | +135.3% |
| Q2 FY2017 | Jun 30, 2017 | $26.35M | – |
| Q1 FY2017 | Mar 31, 2017 | $36.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $45.58M | – |
| Q3 FY2016 | Sep 30, 2016 | $51.88M | – |
See a number that looks wrong?